Study on the cough rate and safety of Xuanbai Chengqi Decoction in treating severe pneumonia with phlegm-heat congestion in the lungs and cough
宣白承气汤治疗痰热壅肺型重症肺炎伴咳嗽患者咳嗽缓解率及安全性研究

摘要

目的 在痰热壅肺型重症肺炎伴咳嗽患者治疗期间，给予其宣白承气汤治疗，分析临床对咳嗽缓解及安全性各情况的影响。方法 2023年1月-2025年1月，本院60例痰热壅肺型重症肺炎咳嗽患者被纳入研究，按1:1比例分作两组（对照组、观察组），接受差异化治疗方案。区分组别后开展常规西医治疗（对照组）及宣白承气汤辅助治疗（观察组）。总结两组治疗效果。结果 从干预成效来看，观察组治疗总有效率达90.00%，较对照组的70.00%呈现明显优势，经统计学分析（P<0.05）。针对核心症状改善，观察组咳嗽缓解效果亦优于对照组（P<0.05）。在用药安全性维度，两组不良反应发生情况相近（P>0.05）。结论 宣白承气汤辅助治疗重症肺炎患者可提高临床疗效及咳嗽缓解率，且安全性较好。

Abstract

Objective During the treatment of patients with severe pneumonia caused by phlegm-heat congestion in the lungs accompanied by cough, Xuanbai Chengqi Decoction was administered to analyze its clinical impact on cough relief and safety.
Methods From January 2023 to January 2025, 60 patients with severe pneumonia and cough caused by phlegm-heat congestion in the lungs in our hospital were included in the study. They were divided into two groups (control group and observation group) in a 1:1 ratio and received differentiated treatment plans. After distinguishing the groups, conventional Western medical treatment (control group) and Xuanbai Chengqi Decoction as an adjunctive treatment (observation group) were carried out. Summarize the therapeutic effects of the two groups.
Results In terms of intervention effectiveness, the total effective rate of treatment in the observation group reached 90.00%, which was significantly higher than that of the control group (70.00%), as analyzed statistically (P<0.05). For the improvement of core symptoms, the cough relief effect of the observation group was also better than that of the control group (P<0.05). In terms of medication safety, the occurrence of adverse reactions was similar in the two groups (P>0.05).
Conclusion   Xuanbai Chengqi Decoction as an adjunctive treatment for patients with severe pneumonia can improve the clinical efficacy and cough relief rate, and has good safety.